CA3218171A1 - Dosage regimens for ecubectedin - Google Patents

Dosage regimens for ecubectedin Download PDF

Info

Publication number
CA3218171A1
CA3218171A1 CA3218171A CA3218171A CA3218171A1 CA 3218171 A1 CA3218171 A1 CA 3218171A1 CA 3218171 A CA3218171 A CA 3218171A CA 3218171 A CA3218171 A CA 3218171A CA 3218171 A1 CA3218171 A1 CA 3218171A1
Authority
CA
Canada
Prior art keywords
compound
dose
cancer
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218171A
Other languages
English (en)
French (fr)
Inventor
Carmen KAHATT
Pilar LARDELLI
Cristian FERNANDEZ
Arturo Soto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CA3218171A1 publication Critical patent/CA3218171A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3218171A 2021-05-19 2022-05-19 Dosage regimens for ecubectedin Pending CA3218171A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382455.0 2021-05-19
EP21382455 2021-05-19
PCT/EP2022/063653 WO2022243482A1 (en) 2021-05-19 2022-05-19 Dosage regimens for ecubectedin

Publications (1)

Publication Number Publication Date
CA3218171A1 true CA3218171A1 (en) 2022-11-24

Family

ID=76197383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218171A Pending CA3218171A1 (en) 2021-05-19 2022-05-19 Dosage regimens for ecubectedin

Country Status (11)

Country Link
US (1) US20240277705A1 (https=)
EP (1) EP4340841A1 (https=)
JP (1) JP2024521122A (https=)
KR (1) KR20240009437A (https=)
CN (1) CN117295499A (https=)
AU (1) AU2022277799A1 (https=)
CA (1) CA3218171A1 (https=)
IL (1) IL308389A (https=)
MX (1) MX2023013715A (https=)
TW (1) TW202313039A (https=)
WO (1) WO2022243482A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
TW202547489A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
JP2024521122A (ja) 2024-05-28
US20240277705A1 (en) 2024-08-22
CN117295499A (zh) 2023-12-26
EP4340841A1 (en) 2024-03-27
WO2022243482A1 (en) 2022-11-24
MX2023013715A (es) 2024-03-26
KR20240009437A (ko) 2024-01-22
AU2022277799A1 (en) 2023-12-21
TW202313039A (zh) 2023-04-01
IL308389A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
US20240277705A1 (en) Dosage regimens for ecubectedin
US20220249528A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
JP2019011376A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
Lewin et al. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS)
US20240415834A1 (en) Lurbinectedin and atezolizumab combinations
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
WO2022101255A1 (en) Lurbinectedin and irinotecan combinations
CA2936783A1 (en) Pharmaceutical combinations
US11911374B2 (en) Methods and uses for treating cancer
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
WO2025217597A1 (en) A cdk9 inhibitor for use in the treatment of cancer in a subject having an asxl1 mutation
AU2023382514A1 (en) Lurbinectedin and doxorubicin combination

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509